Rob is the Founder and a Managing Partner of Elm Street Ventures, a New Haven-based seed and early stage venture capital fund that he founded in 2006, working closely with the Yale Investment Office and Yale Ventures. Since inception, ESV has invested in 32 companies, of which 19 have licensed Yale technology. Rob serves on the boards of P2 Science (where he is Chairman) and Allyx Therapeutics, both Yale spinouts. He also serves on the boards of BioCT and Carbon Containment Lab. Previously, He was a board member of AxioMx, Occam Sciences, SeeClickFix, ShareGrove, and Retail Optimization Inc., and served as an observer on the boards of Affomix, Arvinas (where ESV was the initial investor), BioRelix, Device42, Halda Therapeutics, and Metagenomix. He has a BS in Engineering and Applied Science from Yale University and an MPPM from the Yale School of Management, where he is a Lecturer in entrepreneurship. Rob is a Licensed Professional Engineer and holds several U.S. and foreign patents. He served on the Operating Board of the Yale Entrepreneurial Institute from 2007 to 2017, on the Investment Committee of the College Street Innovation Fund (formerly the YEI Innovation Fund), which ESV managed, and on the Board of New Haven Innovation Collaborative. He is an Entrepreneur-in-Residence at Yale Ventures.